INQOVI is for the treatment of adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML), two blood malignancies
Biologics, as part of a recent reorganization, is now joining McKesson’s Provider Solutions business within the Pharmaceutical Solutions and Services (PSaS) business unit
Trodelvy is the first anti-Trop-2 ADC recently approved by the FDA for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease
McKesson Corporation announced a multi-year strategic growth initiative in 2018, focused on creating innovative new solutions that improve patient care delivery and drive incremental profit growth. The initiative comprises multiple growth pillars, and includes a comprehensive review of the company’s operations and cost structure, designed to increase efficiency, accelerate execution and improve long-term performance. McKesson’s […]
Amber Specialty Pharmacy leads patient satisfaction. Amber Pharmacy, a wholly owned subsidiary of Hy-Vee, is the No. 1 ranked specialty pharmacy in the U.S. for patient satisfaction with pharmacy employees, according to a recent Zitter Health Insights survey. The survey assessed numerous aspects of patient satisfaction and garnered responses from more than 3,000 patients across 38 […]
Many of the 2016 top healthcare market trends began back in 2012-to-2014, and finally emerged more clearly in 2015 for commercially insured populations. This year Access Market Intelligence identifies four (4) major themes emerging that creates the top trends to watch in 2016 into 2017. Themes encapsulating the Top Trends are Macro Issues Trending […]
Limited Distribution Networks growth continues as Specialty Pharmacies compete to be chosen to distribute specialty pharmaceuticals. AMI’s report, Distribution Decision-Making for Specialty Drugs, found that Pharmaceutical manufacturers typically develop a product-specific distribution strategy dependent on company-specific criteria when bringing a new specialty drug to the market. Pharmaceutical manufacturers consider approximately 100-150 different specialty pharmacies (SPs) […]
Since Virginia became the first state in May 2013 to enact legislation regulating a pharmacist’s substitution of an interchangeable biologic drug for a prescribed reference biologic drug, there has not been much activity or clarity on the issue. This issue continues to pit manufacturer versus manufacturer, and other stakeholders against each other in the policy […]